Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Vesigen Therapeutics
Vesigen Therapeutics

Vesigen Therapeutics

Series B

Vesigen Therapeutics: A biotech firm innovating therapies via patented ARMMs technology.

HQ
Cambridge, MA, US
Founded
2019
Overview
Compare
Fundraising
Employees

Founded with a mission to advance groundbreaking therapies, Vesigen Therapeutics is a biotechnology company focused on overcoming delivery barriers to unlock novel treatments. The company leverages its patented ARMMs (ARRDC1 Mediated Microvesicles) technology to efficiently deliver gene editors, proteins, and RNA to intracellular targets. This non-viral platform aims to expand the universe of druggable targets, offering innovative solutions for various medical conditions.

Vesigen Therapeutics has attracted notable investors and industry experts, contributing to its rapid growth and development. The company's ARMMs technology has garnered significant attention for its potential to revolutionize therapeutic delivery. By enabling more efficient and targeted delivery mechanisms, Vesigen is poised to make a substantial impact on the biotechnology landscape, driving forward the possibilities for novel and effective treatments.

Vesigen Therapeutics - Similar Companies

Strm.Bio logo

Strm.Bio

strm.bio

Carmine Therapeutics logo

Carmine Therapeutics

Arrakis Therapeutics logo

Arrakis Therapeutics

arrakistx.com

Rampart Bioscience logo

Rampart Bioscience

rampartbio.com

Faze Medicines logo

Faze Medicines

fazemed.com

ReviR Therapeutics logo

ReviR Therapeutics

revirtx.com

Ring Therapeutics logo

Ring Therapeutics

ringtx.com

Adarx Pharmaceuticals logo

Adarx Pharmaceuticals

adarx.com

Lattice Therapeutics logo

Lattice Therapeutics

Exegenesis Bio logo

Exegenesis Bio

exegenesisbio.com

Sivec Biotechnologies logo

Sivec Biotechnologies

Cargene logo

Cargene

cargene.com

Mantra Bio logo

Mantra Bio

mantrabio.com

Ampersand Biomedicines logo

Ampersand Biomedicines

ampersand.bio

PepVax logo

PepVax

pepvax.co

Vesigen Therapeutics - Quick Facts

Who are Vesigen Therapeutics' competitors?

Companies similar to Vesigen Therapeutics include Strm.Bio, Carmine Therapeutics, Arrakis Therapeutics and Rampart Bioscience.

When was Vesigen Therapeutics founded?

Vesigen Therapeutics was founded in 2019.

Where is Vesigen Therapeutics' headquarters located?

Vesigen Therapeutics' headquarters is located in Cambridge, MA, US.

How much has Vesigen Therapeutics raised to-date?

As of Mar 14, 2023, Vesigen Therapeutics has raised a total of $28.5M (USD).

How many employees does Vesigen Therapeutics have?

Vesigen Therapeutics has 42 employees as of Feb 4, 2024.

Vesigen Therapeutics - Classification

Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Therapies
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 4 more industry codes
NAICS
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified